null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223920

Enrollment

780

Registered

2018-06-01

Start date

2018-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Lenvatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investi

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy efficacy	—

Secondary

Measure	Time frame
efficacy efficacy safety pharmacokinetics safety efficacy	—

Countries

Europe, Japan, North America

Outcome results